Sight Sciences, Inc. (SGHT)

Market Cap	130.90M
Revenue (ttm)	79.87M
Net Income (ttm)	-51.51M
Shares Out	51.33M
EPS (ttm)	-1.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68,045
Open	2.700
Previous Close	2.740
Day's Range	2.540 - 2.730
52-Week Range	2.170 - 8.450
Beta	2.51
Analysts	Buy
Price Target	3.83 (+50.2%)
Earnings Date	Mar 5, 2025

About SGHT

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform procedures for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraoc...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 15, 2021
• Employees: 216
• Stock Exchange: NASDAQ
• Ticker Symbol: SGHT
• Website: https://www.sightsciences.com

Financial Performance

In 2024, Sight Sciences's revenue was $79.87 million, a decrease of -1.47% compared to the previous year's $81.06 million. Losses were -$51.51 million, -7.27% less than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for SGHT stock is "Buy." The 12-month stock price forecast is $3.83, which is an increase of 50.20% from the latest price.

Price Target

$3.83

(50.20% upside)

Analyst Consensus: Buy